DR-118 The role of chromosomal catastrophe in breast cancer pathogenesis
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-118 The role of chromosomal catastrophe in breast cancer pathogenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is thought to be …
DR-115 The association between the homozygous germline deletion of chromosome 8 (ADAM3A region) and survival of patients with the tumours of digestive system treated with different regimens.
Oesophageal adenocarcinoma (EAC) is an aggressive cancer with a poor overall prognosis. Our data from shallow sequencing of 95 patients …
DR-099 PEGASUS – Pancreatic and EsophagoGastric cAncer, improving Survival and qUality of life through personalized medicine
Pancreatic cancer and esophagogastric cancer are among the most deadly forms of cancer: despite intensive treatment with chemotherapy and / …
DR-095 Towards the clinical implementation of whole-genome sequencing (WGS) to guide precision oncology
If we are able to better predict who will respond to treatment, this could have major implications for clinical practice. …
DR-094 RNA (immune) markers in non-small cell lung cancer patients treated with immune checkpoint inhibitors (RIMINI)
Immunotherapy can achieve great results for NSCLC patients, yet this costly therapy is only efficient in a small number of …
DR-093 Whole genome Sequencing to estimate TEmozolomide Associated Response IN Gliomas (STEARING)
“Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Since 2005, standard treatment consists of …
DR-155 Towards personalized cancer therapy: identifying genomic and transcriptomic features predictive of treatment response in patients with castration resistant prostate cancer.
For prostate cancer, identifying patients at risk for developing aggressive disease is clinically challenging [1]. This project aims to discover …
DR-154 Understanding co-effect of inherited and somatic alterations in cancer
Recent studies emphasize the importance of combined effects of germline and somatic alterations in cancer. The aim of the project …
DR-152 Cancer evolutionary dynamics
Cancers change over time. Understanding how cancers change is important for determining a patient’s prognosis and to improve the effectiveness …
DR-151 Characterizing the role of structural variations in prostate cancer
While mutations affecting protein-coding regions have been examined in prostate cancer, structural variants at the genome-wide level are still poorly …
DR-150 Discovery and Characterization of Cancer Driver Mutations in Noncoding regions
Cancer genomes harbor a substantial number of mutations, but only some contribute to tumor development. These so-called driver mutations serve …
DR-149 Discovery and Characterization of Mutational Processes and Cancer Driver Mutations in Melanoma
The discovery of driver mutations and mutational processes in melanoma is complicated by high background mutation rates. With expanded melanoma …
Unieke dataset Hartwig heeft onze visie op uitgezaaide kanker verrijkt.